Capastat Sulfate Side Effects Center

Last updated on RxList: 1/28/2022
Capastat Sulfate Side Effects Center

What Is Capastat Sulfate?

Capastat Sulfate (capremycin) for Injection is an antibiotic used to treat Mycobacterium tuberculosis. Capastat Sulfate is usually given after other tuberculosis medications have been tried without successful treatment of the infection.

What Are Side Effects of Capastat Sulfate?

Common side effects of Capastat Sulfate include:

  • skin rash
  • fever
  • chills
  • body aches
  • flu symptoms, and
  • injection site reactions (pain, irritation, swelling, or a hard lump)

Dosage for Capastat Sulfate

Capastat Sulfate may be administered intramuscularly or intravenously. The usual dose is 1 g daily (not to exceed 20 mg/kg/day) given intramuscularly or intravenously for 60 to 120 days, followed by 1 g by either route 2 or 3 times weekly.

What Drugs, Substances, or Supplements Interact with Capastat Sulfate?

Capastat Sulfate may interact with other antibiotics, lithium, methotrexate, pain or arthritis medicines, medicines used to treat ulcerative colitis, medicines used to prevent organ transplant rejection, antiviral medicines, or cancer medicines. Tell your doctor all medications and supplements you use.

Capastat Sulfate During Pregnancy or Breastfeeding

During pregnancy, Capastat Sulfate should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

Additional Information

Our Capastat Sulfate (capremycin) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Bowel regularity means a bowel movement every day. See Answer
Capastat Sulfate Consumer Information

Get emergency medical help if you have any of these signs of an allergic reaction: hives, itching, rash; fever; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • swelling, rapid weight gain, little or no urinating;
  • severe dizziness, spinning sensation, ringing or roaring sound in your ears, hearing loss;
  • skin rash, bruising, severe tingling, numbness, pain, muscle weakness;
  • low calcium--numbness or tingly feeling around your mouth, fast or slow heart rate, muscle tightness or contraction, overactive reflexes; or
  • low potassium--confusion, uneven heart rate, extreme thirst, increased urination, leg discomfort, muscle weakness or limp feeling.

Common side effects may include:

  • pain, swelling, or a hard lump where the injection was given.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Capastat Sulfate (Capreomycin for Injection)


Fungal Skin Infections: Types, Symptoms, and Treatments See Slideshow
Capastat Sulfate Professional Information



In 36% of 722 patients treated with Capastat Sulfate, elevation of the BUN above 20 mg/100 mL has been observed. In many instances, there was also depression of PSP excretion and abnormal urine sediment. In 10% of this series, the BUN elevation exceeded 30 mg/100 mL.

Toxic nephritis was reported in 1 patient with tuberculosis and portal cirrhosis who was treated with Capastat Sulfate (1 gram) and aminosalicylic acid daily for 1 month. This patient developed renal insufficiency and oliguria and died. Autopsy showed subsiding acute tubular necrosis.

Electrolyte disturbances including hypokalemia, hypomagnesemia and hypocalcemia, sometimes serious in nature, have been reported.


Subclinical auditory loss was noted in approximately 11% of 722 patients undergoing treatment with Capastat Sulfate. This was a 5- to 10- decibel loss in the 4000- to 8000-CPS range. Clinically apparent hearing loss occurred in 3% of the 722 subjects. Some audiometric changes were reversible. Other cases with permanent loss were not progressive following withdrawal of Capastat Sulfate.

Tinnitus and vertigo have occurred.


Serial tests of liver function have demonstrated a decrease in BSP excretion without change in AST (SGOT) or ALT (SGPT) in the presence of preexisting liver disease. Abnormal results in liver function tests have occurred in many persons receiving Capastat Sulfate in combination with other antituberculosis agents that also are known to cause changes in hepatic function. The role of Capastat Sulfate in producing these abnormalities is not clear; however, periodic determinations of liver function are recommended.


Leukocytosis and leukopenia have been observed. The majority of patients treated have had eosinophilia exceeding 5% while receiving daily injections of Capastat Sulfate. This has subsided with reduction of the Capastat Sulfate dosage to 2 or 3 grams weekly.

Pain and induration at the injection site have been observed. Excessive bleeding at the injection site has been reported. Sterile abscesses have been noted. Rare cases of thrombocytopenia have been reported.


Urticaria and maculopapular skin rashes associated in some cases with febrile reactions have been reported when Capastat Sulfate and other antituberculosis drugs were given concomitantly.


For neuromuscular blocking action of this drug, see PRECAUTIONS, General.

Read the entire FDA prescribing information for Capastat Sulfate (Capreomycin for Injection)

© Capastat Sulfate Patient Information is supplied by Cerner Multum, Inc. and Capastat Sulfate Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors